VIP · Research brief
VIP vs Vasoactive Intestinal Peptide — Same Molecule
Short answer
VIP and vasoactive intestinal peptide aren't two different things. They're the exact same molecule. VIP is just the acronym researchers use because typing 'vasoactive intestinal peptide' every time would take forever. The confusion comes from seeing both names in literature, supplement labels, and research peptide catalogs without realizing they're identical.
Key takeaways
- VIP and vasoactive intestinal peptide are the exact same 28-amino-acid neuropeptide. VIP is simply the acronym used in research literature after the first mention.
- The molecule was discovered in 1970 in porcine duodenum by Said and Mutt at the Karolinska Institute, which is why it's named 'intestinal' despite functioning systemically.
- VIP binds to two G-protein-coupled receptors (VPAC1 and VPAC2) that are distributed across the brain, immune system, gut, and smooth muscle. Not just the intestine.
- In scientific writing, the full name 'vasoactive intestinal peptide' appears once at first mention, followed by '(VIP)'. Every subsequent reference uses the acronym.
- Research-grade VIP from suppliers like Real Peptides is synthesized to the same 28-amino-acid sequence regardless of whether the product label uses the acronym or the full name.
VIP and vasoactive intestinal peptide aren't two different things. They're the exact same molecule. VIP is just the acronym researchers use because typing 'vasoactive intestinal peptide' every time would take forever. The confusion comes from seeing both names in literature, supplement labels, and research peptide catalogs without realizing they're identical. The peptide was first isolated from porcine duodenum in 1970 by Said and Mutt at the Karolinska Institute. The name 'vasoactive intestinal peptide' reflects its original discovery site and its ability to dilate blood vessels, but the molecule functions far beyond the gut.
Our team works with researchers who order VIP for studies ranging from neuroinflammation to circadian rhythm modulation. The question comes up constantly. 'Is VIP different from vasoactive intestinal peptide?'. And the answer is always no.
What's the difference between VIP and vasoactive intestinal peptide?
There is no difference. VIP is the acronym for vasoactive intestinal peptide. Both refer to the same 28-amino-acid neuropeptide that acts as a neurotransmitter, hormone, and immune modulator throughout the body. The molecule was named for its discovery site in the intestine and its vasodilatory effects, but it functions in the brain, lungs, and immune system as well. The acronym VIP is used universally in research literature because it's faster to write.
Why the Name 'Vasoactive Intestinal Peptide' Is Misleading
The name 'vasoactive intestinal peptide' makes it sound like this molecule only affects blood vessels in the gut. Which is technically where it was first isolated, but functionally incomplete. VIP (vasoactive intestinal peptide) is a 28-amino-acid neuropeptide that belongs to the secretin/glucagon superfamily, and it's distributed throughout the central nervous system, peripheral nervous system, and immune tissues. The highest concentrations are found in the hypothalamus, cerebral cortex, and gut. But VIP receptors (VPAC1 and VPAC2) exist on neurons, immune cells, smooth muscle, and endothelial tissue across the entire body.
The 'vasoactive' part refers to its ability to relax vascular smooth muscle through nitric oxide (NO) and cyclic AMP pathways, causing vasodilation. The 'intestinal' part reflects its discovery in the duodenum during experiments on gastrointestinal motility. Said and Mutt were studying secretin analogs when they isolated VIP from pig intestinal extracts. The 'peptide' part is straightforward. It's a short chain of amino acids (28 residues, to be exact).
But here's what the name doesn't tell you: VIP modulates T-cell differentiation, suppresses pro-inflammatory cytokines (TNF-α, IL-6, IL-12), regulates circadian rhythm through the suprachiasmatic nucleus, and acts as a neuroprotective agent in models of Alzheimer's and Parkinson's disease. Calling it an 'intestinal' peptide undersells its systemic role. In our experience guiding researchers through peptide selection, VIP is more accurately described as a pleiotropic signaling molecule with neuroimmune, circadian, and metabolic functions. The gut connection is real, but it's one function among many.
VIP Receptor Types and Tissue Distribution
VIP (vasoactive intestinal peptide) exerts its effects by binding to two G-protein-coupled receptors: VPAC1 and VPAC2. Both receptors have equal affinity for VIP and another related peptide called PACAP (pituitary adenylate cyclase-activating polypeptide), but their tissue distribution and downstream signaling differ meaningfully. VPAC1 is expressed broadly across the brain, lungs, liver, intestine, and immune cells. It's the dominant receptor in T-lymphocytes and macrophages, which is why VIP has such potent immunomodulatory effects. VPAC2 is concentrated in the suprachiasmatic nucleus (the brain's circadian clock), smooth muscle, and pancreatic beta cells.
When VIP binds to either receptor, it activates adenylate cyclase, increasing intracellular cyclic AMP (cAMP). This triggers downstream signaling cascades that regulate gene transcription, ion channel activity, and inflammatory mediator release. In neurons, elevated cAMP enhances synaptic plasticity and neuroprotection. In immune cells, it shifts the balance from Th1 (pro-inflammatory) to Th2 (regulatory) responses, suppressing cytokines like IL-12 and TNF-α while upregulating anti-inflammatory IL-10.
The receptor distribution explains why VIP has such diverse effects: VPAC1 dominance in immune tissue makes it a research target for autoimmune and inflammatory conditions, while VPAC2 concentration in the suprachiasmatic nucleus ties it to circadian rhythm regulation and sleep-wake cycle stability. Researchers working with Real Peptides VIP formulations typically target one pathway or the other depending on study design. Immune modulation studies focus on VPAC1-rich tissues, while circadian or metabolic studies target VPAC2-dense regions.
When You'd See 'VIP' vs 'Vasoactive Intestinal Peptide' Written Out
In research literature, you'll see the full name 'vasoactive intestinal peptide' written out exactly once. In the first mention of the molecule in a paper's abstract or introduction, followed immediately by '(VIP)' in parentheses. Every subsequent reference uses the acronym. This is standard scientific writing convention: define the acronym on first use, then use the acronym for the rest of the document. You'll almost never see 'vasoactive intestinal peptide' spelled out repeatedly unless the author is unfamiliar with standard nomenclature or the publication has unusual style rules.
On supplement labels or research peptide supplier sites, you might see both 'VIP' and 'Vasoactive Intestinal Peptide' used interchangeably in product descriptions. Usually because the full name is more SEO-friendly and helps customers who are searching for the spelled-out term rather than the acronym. At Real Peptides, we list both the acronym and the full chemical name in catalog entries to avoid confusion, but the product itself is identical regardless of which name is used. The peptide sequence is the same, the purity standards are the same, and the storage requirements are the same.
In clinical or pharmacological contexts, you'll sometimes see 'VIP' capitalized without periods (VIP, not V.I.P.) to distinguish it from 'very important person'. But this is context-dependent. If you're reading a paper on neuropeptides, 'VIP' unambiguously means vasoactive intestinal peptide. If you're reading a hospitality industry report, it probably doesn't.
VIP vs Vasoactive Intestinal Peptide: Research Grade Comparison
| Feature | VIP (Acronym Form) | Vasoactive Intestinal Peptide (Full Name) | Bottom Line |
|---|---|---|---|
| Chemical Identity | 28-amino-acid neuropeptide from secretin superfamily | Identical. Same 28-amino-acid sequence | No structural difference. Same molecule |
| Amino Acid Sequence | HSDAVFTDNYTRLRKQMAVKKYLNSILN | Identical sequence. Abbreviation doesn't change structure | The name is cosmetic. The peptide is the same |
| Receptor Targets | VPAC1, VPAC2 | VPAC1, VPAC2 | Both names refer to the same receptor-binding molecule |
| Tissue Distribution | CNS, PNS, gut, immune cells, vasculature | Identical distribution. Found in same tissues | Location independent of naming convention |
| Primary Functions | Vasodilation, immune modulation, circadian regulation | Same functions. Neuroprotection, anti-inflammatory, GI motility | Functional profile unchanged by nomenclature |
| Research Applications | Neuroinflammation, autoimmune models, circadian studies | Identical applications. Same experimental uses | Literature uses 'VIP' almost exclusively |
What If: VIP vs Vasoactive Intestinal Peptide Scenarios
What If I See a Product Labeled 'VIP Peptide' — Is That Different from 'Vasoactive Intestinal Peptide'?
No. It's the same molecule. 'VIP peptide' is redundant phrasing (VIP already stands for 'vasoactive intestinal peptide'), but suppliers sometimes write it that way for clarity or SEO purposes. The peptide sequence, purity, and function are identical whether the label says 'VIP', 'VIP peptide', or 'Vasoactive Intestinal Peptide'. What matters is the Certificate of Analysis (CoA) showing purity ≥98% and correct mass spectrometry confirmation. Not the product name.
What If a Research Paper Uses Only the Acronym 'VIP' Without Defining It — How Do I Know It's Vasoactive Intestinal Peptide?
Context clues tell you immediately. If the paper discusses neuropeptides, immune modulation, circadian rhythms, or VPAC receptors, 'VIP' definitively means vasoactive intestinal peptide. If the paper is outside biomedical research (business, hospitality, event planning), 'VIP' likely means something else. In our experience reviewing thousands of peptide research protocols, 'VIP' in a biological sciences context has never referred to anything other than vasoactive intestinal peptide.
What If I'm Ordering Research Peptides and the Catalog Lists Both 'VIP' and 'Vasoactive Intestinal Peptide' as Separate Products?
That would be an error. Contact the supplier for clarification. No legitimate peptide supplier sells 'VIP' and 'vasoactive intestinal peptide' as distinct products because they're the same molecule. If a catalog lists them separately with different CAS numbers, SKU codes, or pricing, one entry is mislabeled. At Real Peptides, we use a single SKU for VIP with both the acronym and full name in the product description to avoid this exact confusion.
The Blunt Truth About VIP vs Vasoactive Intestinal Peptide
Here's the honest answer: this isn't a 'versus' comparison. It's the same peptide with two names. The confusion exists entirely because people see 'VIP' written in shorthand on research protocols or supplement labels and assume it's a different molecule from 'vasoactive intestinal peptide' spelled out in full. It's not. The acronym was adopted decades ago because writing 'vasoactive intestinal peptide' repeatedly in a 10-page research paper wastes time and space. Every credible source. PubChem, UniProt, the IUPHAR/BPS Guide to Pharmacology. Confirms that VIP and vasoactive intestinal peptide share the same CAS number (37221-79-7), the same amino acid sequence, and the same biological function. If you're choosing between two products labeled differently, you're not choosing between two peptides. You're choosing between two suppliers selling the same thing.
The only real difference is the name on the label. The molecule inside is identical. If a supplier tells you otherwise, find a different supplier. At Real Peptides, every batch of VIP (or 'vasoactive intestinal peptide' if you prefer the full name) is synthesized to the same 28-amino-acid sequence with ≥98% purity verified by HPLC and mass spectrometry. Because there's only one correct sequence, and it doesn't change based on what you call it.
VIP and vasoactive intestinal peptide are the same molecule. The acronym is standard shorthand in research, and the full name is what you'll see in formal introductions or product descriptions. The peptide's function, receptor targets, and amino acid sequence are identical regardless of which name is used. If you're ordering research-grade peptides, confirm purity with a Certificate of Analysis and verify the sequence matches the 28-amino-acid structure. The label can say 'VIP', 'vasoactive intestinal peptide', or 'VIP peptide', but the molecule inside should always be the same.
References
Peer-reviewed sources on VIP (Vasoactive Intestinal Peptide) indexed in PubMed, listed for research context. Real Peptides supplies VIP (Vasoactive Intestinal Peptide) for laboratory research use only.
- Vasoactive Intestinal Peptide-Secreting Pheochromocytoma: A Case Report and Review of Literature. AACE clinical case reports, 2022. PMID 35959082. doi:10.1016/j.aace.2022.03.003
- Vasoactive Intestinal Peptide-Secreting Tumors: A Review. Pancreas, 2019. PMID 31609932. doi:10.1097/MPA.0000000000001402
- Neuronal VIP shapes intestinal stem cell activity and mucosal immunity. Cell stem cell, 2026. PMID 41795422. doi:10.1016/j.stem.2026.02.001
- Nanoparticle-Driven Tendon Repair: Role of Vasoactive Intestinal Peptide in Immune Modulation and Stem Cell Enhancement. ACS nano, 2025. PMID 40184556. doi:10.1021/acsnano.4c16917
- Contribution of Vasoactive Intestinal Peptide to the Depressant Effects of Glucagon-like Peptide-2 on Neurally Induced Contractile Responses in Mouse Ileal Preparations. International journal of molecular sciences, 2025. PMID 41465229. doi:10.3390/ijms262411797
- Vasoactive Intestinal Peptide: A Neuropeptide that Plays an Important Role in Parkinson's Disease. Current neuropharmacology, 2025. PMID 40353414. doi:10.2174/011570159X374501250425045109
- Suprachiasmatic Nucleus Vasoactive Intestinal Peptide Neurons Mediate Light-induced Transient Forgetting. Neuroscience bulletin, 2025. PMID 40670769. doi:10.1007/s12264-025-01456-7
- Vasoactive Intestinal Polypeptide Secreting MS Neuroblastoma. Journal of Indian Association of Pediatric Surgeons, 2024. PMID 39691933. doi:10.4103/jiaps.jiaps_104_24
Questions
RESEARCH USE ONLY · NOT EVALUATED BY THE FDA